← IndicationsOpen filtered programs
Landscape
Congenital Hearing Loss
Congenital Hearing Loss has 4 tracked records across 4 named organizations, including 2 strong-evidence records and 1 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.
4
Pipeline Records
strong evidence + caveats + candidates
2
Strong Evidence
2 checked records with caveats
1
Active Programs
currently active
3
Marketed / Approved
commercial or approved
4
Organizations
companies, sponsors, and institutions
Competitive Density
11/100
organization breadth + program volume
Pipeline Velocity
40/100
active and late-stage share
Evidence Coverage
50/100
share strong evidence
Completion Signal
100/100
late-stage, approved, or marketed
Attrition Rate
0/100
share discontinued
Concentration
25/100
top-organization share
Programs by Stage
Approved1 · 25%
Marketed2 · 50%
Observational/NA1 · 25%
Trial / Program Status
Active1 · 25%
Marketed2 · 50%
Approved1 · 25%
Modality Breakdown
Prescription Hearing Aid2 · 50%
BCI/Neurotech1 · 25%
Hearing Aid/Software1 · 25%
Program Types
Device3 · 75%
Software/Neurotech1 · 25%
Top Organizations
Institution-led study1 · 25%
MED-EL1 · 25%
Oticon1 · 25%
Phonak1 · 25%
Population Tags
pediatric4 · 100%
congenital3 · 75%
adult2 · 50%
behind-the-ear2 · 50%
prescription-hearing-aid2 · 50%
auditory-brainstem-implant1 · 25%
cochlear-implant1 · 25%
implantable-neuroprosthesis1 · 25%
power-hearing-aid1 · 25%
profound1 · 25%
Strong-Evidence Programs
2 recordsChecked Records With Caveats
2 recordsOticon Xceed Super Power Hearing Aids
Company: Oticon · Marketed · Marketed
Prescription Hearing AidMarketedMarketed86% confidence
AP-HP LENA language-environment cochlear-implant studyStatus caveat
Sponsor / Institution: Institution-led study · Observational/NA · Active
Hearing Aid/SoftwareObservational/NAActive82% confidence